Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Hydrocodone | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Magnesium sulfate | The therapeutic efficacy of Emylcamate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Emylcamate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Mirtazapine | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Orphenadrine | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Pramipexole | Emylcamate may increase the sedative activities of Pramipexole. |
| Ropinirole | Emylcamate may increase the sedative activities of Ropinirole. |
| Rotigotine | Emylcamate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Emylcamate. |
| Sodium oxybate | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Thalidomide | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of Emylcamate can be increased when used in combination with Yohimbine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Emylcamate. |
| Ethanol | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Emylcamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Emylcamate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Emylcamate is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Emylcamate is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Emylcamate is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Emylcamate is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Emylcamate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Emylcamate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Emylcamate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Emylcamate is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Emylcamate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Emylcamate. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Emylcamate. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Emylcamate. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Emylcamate. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Emylcamate. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Emylcamate. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Emylcamate. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Emylcamate. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Emylcamate. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dosulepin is combined with Emylcamate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Emylcamate is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Emylcamate. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Emylcamate. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Emylcamate. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Emylcamate. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Emylcamate. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Emylcamate. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Emylcamate. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Emylcamate. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Emylcamate. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Emylcamate. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Emylcamate. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Emylcamate. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Emylcamate. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Emylcamate. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Emylcamate. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Emylcamate. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Emylcamate. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Emylcamate. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Emylcamate. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Emylcamate. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Emylcamate. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Emylcamate. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Emylcamate. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Emylcamate. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Emylcamate. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Emylcamate. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Emylcamate. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Emylcamate. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Emylcamate. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Emylcamate. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Emylcamate. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Emylcamate. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Emylcamate. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Emylcamate. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Emylcamate. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Emylcamate. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Emylcamate. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Emylcamate. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Emylcamate. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with Emylcamate. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with Emylcamate. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with Emylcamate. |